{
  "documentMetadata": {
    "title": "Empiric Therapy of Septic Arthritis in Neonates (age < 3 months)",
    "lastUpdated": "2024-02-15",
    "sourceFile": "Arthritis, Septic, Infant.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Empiric therapy of septic arthritis in neonates (age < 3 months).",
        "In General:",
        "Infants with septic arthritis may present with fever and irritability; subtle symptoms such as pain with diaper change may be only signs. Pseudoparalysis can occur.",
        "Treatment of septic arthritis requires both adequate drainage of purulent joint fluid and appropriate antimicrobial therapy.",
        "Start empiric therapy after collection of blood and joint fluid for culture; review Gram stain of joint fluid.",
        "MRI may be helpful to eliminate contiguous osteomyelitis",
        "There is no need to inject antimicrobial agents into joints.",
        "Blood cultures may be positive",
        "PCR can be helpful in diagnosis"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Group B Strep",
        "Staph. aureus",
        "Enterobacteriaceae",
        "Kingella kingae",
        "N. gonorrhoeae",
        "S pneumoniae"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Cefazolin",
            "dose": "100 mg/kg/day",
            "route": "IV",
            "frequency": "divided q8h"
          }
        ],
        "notes": "if prevalence of MRSA < 10-15%"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "appliesTo": {
          "description": "MSSA"
        },
        "components": [
          {
            "drug": "Nafcillin",
            "dose": "200 mg/kg/day",
            "route": "IV",
            "frequency": "divided q6h"
          },
          {
            "drug": "Cefotaxime",
            "dose": "150-200 mg/kg/day",
            "route": "IV",
            "frequency": "divided q8h",
            "connector": "+"
          }
        ],
        "notes": "where available"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Ceftriaxone",
            "dose": "100 mg/kg/day"
          }
        ],
        "notes": "not adequate for definitive therapy of Staph aureus"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "60-80 mg/kg",
            "route": "IV",
            "frequency": "divided 3-4 times a day"
          },
          {
            "drug": "Ceftriaxone",
            "dose": "100 mg/kg/day",
            "connector": "+"
          },
          {
            "drug": "Cefotaxime",
            "dose": "150-200 mg/kg/day",
            "route": "IV",
            "frequency": "divided q8h",
            "connector": "or"
          }
        ],
        "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 10-15 µg/mL but AUC targeting is preferred). Cefotaxime where available"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "components": [
          {
            "drug": "Clindamycin",
            "dose": "30-40 mg/kg/day",
            "frequency": "divided q8h"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Narrow therapy once organism identified based on results of blood or joint fluid culture.",
        "May transition to high dose oral therapy.",
        "Duration not well defined for neonates but 3 weeks of therapy generally considered adequate."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Group B Streptococcus and Staph aureus are the most common community-acquired etiologies.",
        "Cefazolin generally as effective as Nafcillin but fewer adverse events",
        "Vancomycin: traditional dosing of 45-60 mg/kg/day frequently does not achieve target AUC in term infants and older children with normal renal function. Use of AUC24 closer to 400 µg/mL adequate for most non-CNS infections. Clin Infect Dis Jul 13 2020",
        "Blood cultures are frequently positive.",
        "Adjacent bone is involved in 2/3 of patients. MRI helpful",
        "Reference Infect Dis Clin North Am. 2015 Sep;29(3):557-74."
      ]
    }
  ]
}
